abstract |
A pharmaceutical composition for treatment of underlying nonpharmacologically induced central or peripheral nervous system cholinergic deficit state in humans comprising a monoamine acridine derivative of the formula:n n wherein R₁ represents hydrogen, hydroxy, methyl, methoxy, ethyl or ethoxy; R₁ and R₂ together may form a double bond, R₃ and R₄ together may form a double bond, or R₁, R₂, R₃ and R₄ are all hydrogen; R₅ represents hydrogen, hydroxy, methoxy or ethoxy; R₆ represents hydrogen, hydroxy, methoxy or ethoxy; and R₇ is without a substituent or R₇ represents an oxygen atom, a C₁-C₂₀ alkyl radical or a radical selected from the group consisting of n -R-N(R)₂,n n wherein each R is independently selected from C₁-C₂₀ alkyl; or a pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable inert carrier therefor; with the provisos that the monoamine acridine derivative is a compound in which (i) if R₁, R₂, R₃, R₄, R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, (ii) if R₁ and R₂ together form a double bond, R₃ and R₄ together form a double bond and R₅ and R₆ are each hydrogen, then R₇ cannot be without a substituent, and (iii) if R₃ and R₄ together form a double bond and R₇ is without a substituent, then R₁ cannot be a hydrogen atom is provided. |